Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Therapeutic Drug Monitoring Market Forecasts Growth from $2.55B (2026) to $4.16B by 2032, Profiling Waters, Sekisui Diagnostics, ARUP Labs & 9 Other Key Players

globenewswire.com
ABT Abbott Laboratories is mentioned as a key player in the Therapeutic Drug Monitoring market, which is projected to grow significantly. The article does not provide specific sentiment towards Abbott but lists it among other key companies. BIO Bio-Rad Laboratories, Inc. is identified as a key player in the Therapeutic Drug Monitoring market, a sector forecast to grow significantly. The article does not express specific sentiment towards Bio-Rad but includes it among other major companies. LH Laboratory Corporation of America Holdings is named as a key participant in the Therapeutic Drug Monitoring market, which is anticipated to grow substantially. The article does not provide specific sentiment for Labcorp but lists it among other important companies. DGX Quest Diagnostics Incorporated is mentioned as a key player in the Therapeutic Drug Monitoring market, a sector projected for significant growth. The article does not offer specific sentiment for Quest Diagnostics but includes it in a list of key companies. TMO Thermo Fisher Scientific Inc. is identified as a key player in the Therapeutic Drug Monitoring market, which is projected for significant growth. The article does not provide specific sentiment for Thermo Fisher but lists it among other important companies. WAT Waters Corporation is mentioned as a key player in the Therapeutic Drug Monitoring market, which is forecast to grow substantially. The article does not provide specific sentiment for Waters but lists it among other key companies.

Therapeutic Drug Monitoring Market Forecasts Growth from $2.55B (2026) to $4.16B by 2032, Profiling Waters, Sekisui Diagnostics, ARUP Labs & 9 Other Key Players Dublin, Sept. 15, 2026 (GLOBE NEWSWIRE) -- "Therapeutic Drug Monitoring Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering.

The global Therapeutic Drug Monitoring Market research report examines a sector projected to reach USD 2.55 billion in 2026 and grow at a CAGR of 8.52% to USD 4.16 billion by 2032. It provides strategic insight into clinical applications, analytical technologies, artificial intelligence, regional adoption, and emerging opportunities across the precision medicine ecosystem.

Market Overview and Growth Drivers

Therapeutic drug monitoring (TDM) enables clinicians to individualize dosing by measuring drug concentrations and interpreting results alongside patient-specific factors. It is particularly valuable for medicines with narrow therapeutic ranges, variable pharmacokinetics, or substantial toxicity risks, including immunosuppressants, antiepileptics, anti-infectives, oncology therapies, psychiatric medications, and selected biologics.

Growth is supported by aging populations, polypharmacy, organ transplantation, antimicrobial resistance, chronic disease management, and value-based care. TDM can reduce adverse drug reactions, assess medication adherence, and support evidence-based dose adjustments. These findings enable healthcare and diagnostics leaders to prioritize high-value applications and identify attractive investment or market entry opportunities.

Technology and Clinical Transformation

Liquid chromatography-mass spectrometry is improving analytical specificity and multiparameter testing, while immunoassays remain important for routine, high-throughput monitoring. Dried blood spot collection and microsampling can reduce sample requirements and extend access to remote or vulnerable patients. Automation and laboratory information systems are also improving turnaround times and workflow consistency.

TDM is increasingly evolving from an isolated laboratory result into an integrated medication optimization service. Pharmacokinetic modeling, electronic health records, pharmacogenomic context, and decision-support platforms are strengthening exposure-based dosing, particularly in transplant medicine, critical care, and antimicrobial stewardship.

Artificial Intelligence Impact

AI-enabled tools can support Bayesian dose optimization, predict concentration-time profiles, flag anomalous results, and account for kidney function, age, weight, inflammation, drug interactions, adherence, and changing physiology. When integrated with clinical and laboratory systems, these capabilities can support proactive dosing and more efficient result prioritization.

Adoption depends on validated datasets, transparent performance, interoperability, cybersecurity, regulatory compliance, and clinical governance. AI is best positioned as an assistive capability supported by pharmacist, physician, and laboratory oversight. Understanding these implementation risks supports more resilient technology selection and deployment strategies.

Regional and Economic Group Insights

North America and Europe demonstrate mature adoption through established hospital laboratories, transplant programs, stewardship frameworks, and clinical pharmacology expertise. Asia-Pacific is expanding rapidly as China, India, Japan, South Korea, and Australia invest in tertiary care, precision medicine, and advanced diagnostics.

Latin America is progressing through improved hospital capabilities, led by Brazil and Mexico, although reimbursement and laboratory access remain uneven. Gulf countries are investing in specialty hospitals, transplant services, and digital health. African adoption is concentrated in major academic and referral centers, with opportunities in HIV, tuberculosis, infectious disease, and selected transplant programs.

G7 countries lead in Bayesian dosing, mass spectrometry, and multidisciplinary care models. ASEAN, GCC, BRICS, EU, and NATO markets present distinct opportunities shaped by infrastructure, accreditation, reimbursement, workforce capacity, and regional healthcare priorities. Comparative regional analysis helps decision-makers align expansion plans with local readiness and access constraints.

Competitive Priorities and Strategic Actions

Industry participants should focus on clinically validated solutions that improve interpretation and turnaround time, rather than measurement alone. Priority actions include:

. Standardizing sample timing, reporting formats, reference ranges, and consultation pathways.

. Expanding assays for immunosuppressants, anti-infectives, antiepileptics, psychiatric drugs, and specialty therapies.

. Integrating laboratory systems, electronic records, pharmacokinetic software, and clinical decision support.

. Establishing transparent governance and multidisciplinary oversight for AI-enabled dosing.

. Supporting clinician education, pharmacist-led services, accreditation, and outcome-based evidence.

. Using reference laboratories, microsampling, and focused test menus to expand access in emerging markets.

Key Takeaways from This Report

. The market is forecast to increase from USD 2.55 billion in 2026 to USD 4.16 billion by 2032 at an 8.52% CAGR.

. Precision dosing, antimicrobial stewardship, transplantation, and complex chronic care are central demand drivers.

. Mass spectrometry, microsampling, automation, Bayesian modeling, and AI are reshaping TDM workflows.

. Regional adoption varies significantly, creating differentiated opportunities for diagnostics, digital health, laboratories, and healthcare providers.

. Workflow integration, clinical validation, quality governance, and actionable reporting will be key competitive advantages.

Key Attributes:

Key Topics Covered:

1. Preface

1.1. Objectives of the Study

1.2. Market Definition

1.3. Market Segmentation & Coverage

1.4. Years Considered for the Study

1.5. Currency Considered for the Study

1.6. Language Considered for the Study

1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction

2.2. Research Design

2.2.1. Primary Research

2.2.2. Secondary Research

2.3. Research Framework

2.3.1. Qualitative Analysis

2.3.2. Quantitative Analysis

2.4. Market Size Estimation

2.4.1. Top-Down Approach

2.4.2. Bottom-Up Approach

2.5. Data Triangulation

2.6. Research Outcomes

2.7. Research Assumptions

2.8. Research Limitations

3. Executive Summary

3.1. Introduction

3.2. CXO Perspective

3.3. New Revenue Opportunities

3.4. Next-Generation Business Models

3.5. Industry Roadmap

4. Market Overview

4.1. Introduction

4.2. Industry Ecosystem & Value Chain Analysis

4.2.1. Supply-Side Analysis

4.2.2. Demand-Side Analysis

4.2.3. Stakeholder Analysis

4.3. Market Dynamics

4.3.1. Key Drivers

4.3.2. Key Restraints

4.3.3. Key Opportunities

4.3.4. Key Challenges

4.4. Porter's Five Forces Analysis

4.5. PESTLE Analysis

4.6. Market Outlook

4.6.1. Near-Term Market Outlook (0-2 Years)

4.6.2. Medium-Term Market Outlook (3-5 Years)

4.6.3. Long-Term Market Outlook (5-10 Years)

4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective

5.2. Consumer Experience Benchmarking

5.3. Opportunity Mapping

5.4. Distribution Channel Analysis

5.5. Pricing Trend Analysis

5.6. Regulatory Compliance & Standards Framework

5.7. ESG & Sustainability Analysis

5.8. Disruption & Risk Scenarios

5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Therapeutic Drug Monitoring Market, by Product Type

7.1. Introduction

7.2. Instruments

7.2.1. Immunoassay Analyzers

7.2.2. Liquid Chromatography Systems

7.2.3. Mass Spectrometry Systems

7.3. Reagents & Kits

7.3.1. Immunoassay Kits

7.3.2. Liquid Chromatography Reagents

7.3.3. Mass Spectrometry Reagents

7.4. Software & Services

7.4.1. Consulting Services

7.4.2. Data Management Software

8. Therapeutic Drug Monitoring Market, by Technology

8.1. Introduction

8.2. Chromatography

8.2.1. Gas Chromatography

8.2.2. Liquid Chromatography

8.3. Immunoassay

8.3.1. Clia

8.3.2. Elisa

8.3.3. Fia

8.4. Mass Spectrometry

8.4.1. Single Quadrupole Mass Spectrometry

8.4.2. Tandem Mass Spectrometry

9. Therapeutic Drug Monitoring Market, by Drug Class

9.1. Introduction

9.2. Antibiotics

9.3. Anticancer Drugs

9.4. Antiepileptics

9.5. Cardiovascular Drugs

9.6. Immunosuppressants

9.6.1. Antimetabolites

9.6.2. Calcineurin Inhibitors

9.6.3. Mtor Inhibitors

10. Therapeutic Drug Monitoring Market, by Application

10.1. Introduction

10.2. Cardiology

10.3. Infectious Disease

10.3.1. Bacterial Infections

10.3.2. Fungal Infections

10.3.3. Viral Infections

10.4. Neurology

10.5. Oncology

10.5.1. Leukemia

10.5.2. Solid Tumors

10.6. Transplantation

11. Therapeutic Drug Monitoring Market, by End User

11.1. Introduction

11.2. Clinical Laboratories

11.3. Home Healthcare

11.4. Hospitals

11.5. Research Institutes

12. Therapeutic Drug Monitoring Market, by Region

12.1. Introduction

12.2. Asia-Pacific

12.3. North America

12.4. Latin America

12.5. Europe

12.6. Middle East

12.7. Africa

13. Therapeutic Drug Monitoring Market, by Group

13.1. Introduction

13.2. ASEAN

13.3. GCC

13.4. European Union

13.5. BRICS

13.6. G7

13.7. NATO

14. Therapeutic Drug Monitoring Market, by Country

14.1. Introduction

14.2. United States

14.3. Canada

14.4. Mexico

14.5. Brazil

14.6. United Kingdom

14.7. Germany

14.8. France

14.9. Russia

14.10. Italy

14.11. Spain

14.12. China

14.13. India

14.14. Japan

14.15. Australia

14.16. South Korea

15. Competitive Landscape

15.1. Market Share Analysis, 2025

15.2. Market Concentration Analysis, 2025

15.2.1. Concentration Ratio (CR)

15.2.2. Herfindahl Hirschman Index (HHI)

15.3. Recent Developments & Impact Analysis, 2025

15.4. Product Portfolio Analysis, 2025

15.5. Benchmarking Analysis, 2025

16. Company Profiles

16.1. Abbott Laboratories

16.2. ARUP Laboratories

16.3. Bio-Rad Laboratories, Inc.

16.4. Diasorin S.p.A.

16.5. F. Hoffmann-La Roche Ltd.

16.6. Laboratory Corporation of America Holdings

16.7. Quest Diagnostics Incorporated

16.8. Randox Laboratories Ltd.

16.9. Sekisui Diagnostics, LLC

16.10. Siemens Healthineers AG

16.11. Thermo Fisher Scientific Inc.

16.12. Waters Corporation

17. Key Experts

For more information about this report visit https://www.researchandmarkets.com/r/1s2wlr

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.